Eisai said on December 2 that Chinese regulators have accepted for review its multi-kinase inhibitor Lenvima (lenvatinib) for the treatment of differentiated thyroid cancer, which, if approved, would be the second indication in China, after hepatocellular carcinoma (HCC). The submission…
To read the full story
Related Article
- Lenvima Gets China OK for 1st Line HCC: Eisai/Merck
September 6, 2018
BUSINESS
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





